Sobi to share new clinical data and research at EULAR 2025
Sobi will host a symposium on the dermatologic, rheumatologic, and hematologic features of VEXAS syndrome during the congress. The symposium will be chaired by Dr Sophie Georgin-Lavialle MD, PhD from the French National Reference Centre for auto-inflammatory diseases and inflammatory amyloidosis. The symposium will be followed by a panel discussion and Q&A.
"We are delighted that our continued advancements in treating rare disease, including those suffering with the most debilitating rheumatology conditions will be presented at this year's EULAR conference. Sobi's presentations will provide insights and treatment options for those working with patients with rheumatological conditions, providing them with the most up-to-date clinical data and approaches," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi.
"With several poster and oral presentations and a longer form symposium, we are proud to be able to show how research and collaboration can advance clinical practice – and we look forward to meeting and connecting with colleagues in Barcelona," Lydia Abad-Franch concluded.
Key data to be presented at EULAR 2025
Gamifant (emapalumab)
Efficacy and Safety of emapalumab in Patients with Macrophage Activation Syndrome in Still's disease: Results from a Pooled Analysis of Two Prospective Trials
Speaker: Professor Fabrizio De Benedetti (principal investigator of the study)
Oral presentation
Session title: Clinical Abstract Session: Proceedings in Juvenile Idiopathic Arthritis
Session date: Thursday 12 June
Session time: 10:30 - 12:00 CEST
Presentation time: 10:48 - 10:57 CEST
Location: Room 6.1
Exposure-safety analysis from two clinical trials of emapalumab in patients with macrophage activation syndrome in Still's disease
Speaker: Professor Fabrizio De Benedetti (principal investigator of the study)
Poster presentation
Session title: Poster View VI
Session date: Friday 13 June
Session time: 12:00 – 13:30 CEST
Location: Poster Hall
NASP (formerly SEL-212)
Variations in uncontrolled gout between Rheumatologists and Nephrologists
Poster presentation
Session title: Poster View VIII
Session date: Friday 13 June
Session time: 10:15 - 11:45 CEST
Location: Poster Hall
Vonjo (pacritinib)
Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research
Poster presentation
Session title: Poster View VII
Session date: Friday 13 June
Session time: 14 :45 - 15 :45 CEST
Location: Poster Hall
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome
Poster tour
Session Title: Poster Tour II/ Clinical and Basic Poster Tours: Autoinflammatory Diseases including VEXAS
Session date: Saturday 14 June
Session time: 10:15 -11:45 CEST
Presentation time: 10:29 - 10:36 CEST (4 mins + 2 mins Q&A)
Location: Poster Tour II
Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)
Poster tour
Session title: Poster Tour II/ Clinical and Basic Poster Tours: Autoinflammatory Diseases including VEXAS
Session date: Saturday 14 June
Session time: 10:15 - 11:45 CEST
Presentation time: 10:43 - 10:50 CEST (4 mins + 2 mins Q&A)
Location: Poster Tour II
Medical Symposium
An in-depth presentation on VEXAS syndrome: the dermatologic, rheumatologic, and hematologic features of the condition. Followed by a panel discussion and Q&A
Symposium title: Putting on your VEXAS goggles: Seeing what's in plain sight
Session date: Friday 13 June
Session time: 17:30 - 18:30 CEST
Location: Fira de Barcelona, Room B4
About Gamifant® (emapalumab)
Gamifant® (emapalumab) is indicated for the treatment of adult and paediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.
About Macrophage activation syndrome (MAS)
Macrophage activation syndrome (MAS) is a potentially life-threatening complication of Still's disease characterised by interferon-gamma (IFNγ)–driven systemic hyperinflammation. More than one-third of patients inadequately respond to high-dose glucocorticoids. Emapalumab, an anti-IFNγ antibody, demonstrated efficacy and safety in a phase 2 pilot study in patients with MAS in Still's disease and an inadequate response to high-dose glucocorticoids.
About NASP, formerly SEL-212
NASP is a novel investigational medicine designed to reduce serum urate (SU) levels in people with uncontrolled gout, potentially reducing harmful tissue urate deposits which when left untreated can lead to debilitating gout flares and joint deformity. NASP is administered every 4-weeks as a sequential, two-component, infusion therapy consisting of tolerogenic nanoencapsulated sirolimus (NAS) which mitigates the formation of anti-drug antibodies (ADAs) and a uricase, pegadricase (P), which reduces serum uric acid. ADAs develop due to unwanted immune responses to biologic medicines, reducing their efficacy and tolerability, which remains an issue across multiple therapeutic modalities and disease states including uncontrolled gout.
About VONJO® (pacritinib)
VONJO is a kinase inhibitor that is indicated in the US for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
About VEXAS
VEXAS syndrome is a disease that causes inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene of blood cells and acquired later in life. The condition is not genetically inherited.
About Sobi
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-to-share-new-clinical-data-and-research-at-eular-2025,c4156162
The following files are available for download:
https://mb.cision.com/Main/14266/4156162/3474231.pdf
Sobi share New clinical Data and Research at EULAR 2025
View original content:https://www.prnewswire.co.uk/news-releases/sobi-to-share-new-clinical-data-and-research-at-eular-2025-302466843.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
an hour ago
- Health Line
Orforglipron: What to Know About Eli Lilly's New Weight Loss Pill for Obesity
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure. Experts note that some may prefer the flexibility of a weight loss pill compared to the injectable version. Eli Lilly is on track to apply for FDA approval by late 2025, the drugmaker announced. A groundbreaking new oral medication for weight management has shown promising results in a recent large-scale clinical trial, offering hope to millions with obesity and related health issues. Orforglipron, developed by Eli Lilly, is an investigational daily pill that mimics the effects of injectable GLP-1 receptor agonists, a class of drugs known to help with weight loss and blood sugar control. In its pivotal Phase 3 ATTAIN-1 trial, which involved over 3,000 adults with obesity or overweight, orforglipron demonstrated significantly higher weight loss compared to a placebo. Participants titrating up to the highest dose of 36 milligrams lost an average of 12.4% of their initial body weight (27.3 pounds) over the course of the 72-week study. Lower doses (6 milligrams and 12 milligrams) also showed clinically significant weight reductions of 7.8% and 9.3%, respectively. Beyond weight loss, orforglipron improved heart health markers while maintaining a safety profile similar to existing treatments. These improvements included lower levels of non-HDL cholesterol, triglycerides, and systolic blood pressure. At the highest dose, it also reduced high-sensitivity C-reactive protein (hsCRP) by 47.7% With regulatory submissions planned by the end of 2025 and a global launch on the horizon, here is everything you need to know about the new weight loss pill from Eli Lilly. What is orforglipron? Injectable glucon-like peptide-1 (GLP-1) medications have skyrocketed in popularity due to their clinically significant effects on weight loss and the management of certain health conditions. This class of drugs, sometimes referred to as GLP-1 receptor agonists, includes Wegovy (semaglutide) and Zepbound (tirzepatide). Diabetes medications Ozempic and Mounjaro are often prescribed off-label for weight management. Unlike injectable GLP-1 drugs, orforglipron is not a peptide. Peptides are naturally occurring short chains of amino acids whose synthetic versions have found applications in many areas, such as skin care, bodybuilding, and weight loss, due to their ability to trigger desirable effects in the human body. While orforglipron is not a peptide, it can activate the glucagon-like peptide-1 receptor in the same way as GLP-1 medications. 'Orforglipron is a new kind of GLP-1 medication known as a small-molecule oral GLP-1 receptor agonist,' explained Rekha Kumar, MD, an obesity medicine specialist and head of medical affairs at Found. This means orforglipron can be taken in pill form to achieve similar effects, including weight loss and other improvements in metabolic health, like better blood sugar control, lower blood pressure, and reduced cholesterol. Are weight loss pills as effective as injectable GLP-1s? Once-daily oral versions of GLP-1 drugs could replace the need for once-weekly injections, but Eli Lilly isn't the only drug manufacturer with a weight loss pill in the works. Competitor Novo Nordisk's weight loss pill has also produced meaningful weight loss results in clinical trials. The Food and Drug Administration (FDA) recently accepted Novo Nordisk's application to produce its oral version of Wegovy. While clinical trials for both drugmakers' weight loss pills have yielded positive results for weight loss, experts say they may not always be as effective as injectable counterparts. 'That's because orforglipron is a non-peptide, small-molecule pill, so it doesn't bind to the GLP-1 receptor quite as strongly as injectable peptide medications, which mimic our body's natural GLP-1 hormone,' Kumar explained. 'Even so, the results are still very good by any health standard, and for people who prefer a pill over an injection, it's an effective alternative to help reach weight-care goals,' Kumar told Healthline. Some people might prefer weight loss pills over injectables Some people may prefer current injectable GLP-1 medications due to their potential for greater weight loss or the simplicity of weekly injections. For others, the convenience of a once-daily pill like orforglipron might seem more appealing. Kumar noted that many people might prefer a pill over needles, or not having to worry about refrigeration or structured rules about when to inject the medication. According to Eli Lilly's press release, orforglipron can be taken at any time of the day without restrictions on food and water intake. 'It's a great option for people who want a simpler, needle-free treatment that fits easily into busy or unpredictable schedules — like parents, frequent travelers, or anyone who dislikes injections,' Kumar said. There are also the dual factors of cost and availability. Kumar said you can 'expect manufacturing and storage to be easier and cheaper for a pill like this, so once someone starts, they're less likely to face the shortages we saw after Wegovy and Zepbound launched.' This could make orforglipron more accessible to many people, Kumar noted. Side effects of weight loss pill similar to other GLP-1s Meghan Garcia-Webb, MD, triple board certified in internal medicine, lifestyle medicine, and obesity medicine, and an internist at an academic medical center in Boston, noted that orforglipron has shown potentially mild to moderate gastrointestinal side effects. These include nausea, vomiting, constipation, and diarrhea. As Eli Lilly stated in a press release, this is consistent with the overall safety profile of other drugs in this class. About 1 in 10 individuals at the highest tested dose dropped out of the study due to these adverse effects. Importantly, Eli Lilly also stated that there were no observed signs of liver-related side effects. 'Overall it seems like a very promising alternative offering similar results to Wegovy with a similar side effect profile to current GLP-1 RA weight medications,' said Garcia-Webb. When will Lilly's weight loss pill be available? Eli Lilly announced they're planning to submit orforglipron to the FDA for weight loss this year. Garcia-Webb said this means the pill could be approved as early as 2026. The drugmaker stated that Orforglipron's positive Phase 3 ATTAIN-1 trial results have put it on track to submit to global regulatory agencies by the end of 2025. They are also making substantial investments to meet anticipated demand at launch. This indicates that orforglipron could become available to consumers following regulatory approval. However, Eli Lilly cautions about the risks and uncertainties in drug development. There are no guarantees that orforglipron will be approved or make it to market on the anticipated timeline. In the meantime, Novo Nordisk's weight loss pill could come to market sooner, but an exact timeline remains unclear.
Medscape
2 hours ago
- Medscape
New Tools for Lung Cancer, Harder Job for Clinicians
This transcript has been edited for clarity. Hello. It's Mark Kris, from Memorial Sloan Kettering, with a month-later review of the 2025 ASCO meeting in Chicago. I think everybody who was there and attended the lung cancer sessions left with the, I'll have to say, difficult time unpacking what we learned during that meeting. There was a dizzying array of trials presented and a huge amount of data, but sadly, there was no breakthrough. There was no one treatment or approach that told each of us we had to start doing this in every patient on Tuesday when we got home again. What it did was give us more tools and more ways we could fight cancers, but it really made our jobs much harder. I think that we need to spend some time thinking about how those data could be used, and I'll pick a couple of examples. I think one would be in the small cell lung cancer area. There was a large amount of attention to the use of tarlatamab as a treatment at relapse. It was a comparison trial to topotecan and lurbinectedin, and there was an improvement in outcomes in those groups. While that benefit was there, what was not addressed was the benefit of repeating standard therapy, which is what many of us do, particularly when there has been a longer time between the end of the induction treatment and recurrence. The second trial that I thought was useful in the small cell area was a randomized trial adding lurbinectedin to the checkpoint inhibitor after induction chemotherapy. There was an improvement in disease-free survival there also. Personally, I was more impressed by the latter trial, in that it gave our patients a longer time with disease control rather than focusing the time of relapse, where people may already have suffered symptoms brought on by the progressive lung cancer — which sadly is an all-too-common occurrence. In the perioperative space, my colleague Jamie Chaft reported on neoadjuvant osimertinib. In her trial of osimertinib alone, osimertinib plus chemotherapy, and osimertinib and chemotherapy alone, they showed a benefit for the osimertinib-containing arms but not a clear benefit of osimertinib alone versus osimertinib plus chemotherapy. What's the take-home message there? Well, again, it's not simple. I think that we need to give chemotherapy to every patient with stage IB disease and beyond, whether they have an EGFR mutation or not. Based on the fact that we can give chemotherapy more safelyand more completely in the neoadjuvant setting, I would tend to use osimertinib with chemotherapy upfront and then surgery. If you do go the other way and use osimertinib alone, you would need to give chemotherapy afterward, which is, frankly, tougher. I think my take-home message from that was osimertinib and chemotherapy, our standard of care for advanced disease, should also be our standard for neoadjuvant disease in patients with EGFR mutations. There was a fantastic lecture by Patricia LoRusso, from Yale, about antibody-drug conjugates (ADCs). I think that was the most confusing moment of all during the ASCO meeting — the number of ADCs under evaluation. Yet, as Dr LoRusso pointed out, despite the number, it's the same targets, largely the same warheads, and very often, antibodies without activity in and of themselves. When you look at the overall benefits of the group, there are none that truly stand out. We now have three available in the lung cancer arena. The benefit, side effects, and the whole field is really quite confusing. One other message was that, with the bispecific antibodies, the more targets you have, the more toxicity you're going to see. It's a real balance between benefit and risk. What are you going to do? Again, there was no breakthrough at ASCO this year. Clearly, there are more therapies and there are even more in the pipeline. I think what we need to do now is to learn more, and to — unfortunately — spend a large amount of time going through the data and see exactly the benefit versus risk ratio for each of the new therapies and for each of our patients deciding where that goes. For example, I would be a big fan of giving lurbinectedin because of its ability to improve disease-free survival, which is so important in small cell [lung cancer], where relapse is almost certain, and that disease-free time is the best time for our patients. For the neoadjuvant, it would be giving both chemotherapy and osimertinibpre-surgery, in that is better tolerated there and you can also assess benefit very well. For tarlatamab, it's a tough decision there. Again, it's the time of relapse. We have many choices at relapse, giving the same drugs again, giving another perhaps less toxic agent like temozolomide, giving tarlatamab and the standard drugs. Clearly, tarlatamab was better than some of the standard drugs, but they're not the ones that most of us use for the patients. We usually go with the same treatment by and large. Lastly, it's going to be incumbent on us to work harder to take that information we got at ASCO this year and make the best decisions for each patient. We have to focus on the nuance. We have to learn more, and there is no knee-jerk that every patient needs tarlatamab or every patient should get induction chemotherapy with the combination. We have to choose our patients wisely. You've heard me before, and I'll say it again. Our jobs are better, but they're harder.
Yahoo
3 hours ago
- Yahoo
Germany and allies to send major military aid package to Ukraine using new NATO supply line
Russia Ukraine War BERLIN (AP) — Germany announced on Wednesday that it will work with a group of Ukraine's Western backers to supply a package of military aid to the war-ravaged country worth up to $500 million using a new NATO supply line. Earlier this month, NATO started coordinating regular deliveries of large weapons packages to Ukraine after the Netherlands said that it would provide air defense equipment, ammunition and other military aid worth 500 million euros ($582 million). Sweden announced the following day that it would contribute $275 million to a joint effort along with its Nordic neighbors Denmark and Norway to provide $500 million worth of air defenses, anti-tank weapons, ammunition and spare parts. Germany's foreign and defense ministries said the support is focused on equipment like 'critical air defense capabilities. These are urgently needed to defend against Russia's ongoing air strikes, which are killing more and more civilians throughout Ukraine.' The United Nations has said that Russia's relentless pounding of urban areas behind the front line has killed more than 12,000 Ukrainian civilians. Two deliveries of equipment, most of it bought in the United States, were scheduled for this month, although the Nordic package was more likely to arrive in September. Germany did not name the group of countries it would be working with. The equipment is supplied based on Ukraine's priority needs on the battlefield. NATO allies then locate the weapons and ammunition and send them on. Germany has delivered or pledged military support to Ukraine worth around 40 billion euros ($47 billion) since Russia launched its full-scale invasion in February 2022. Solve the daily Crossword
